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Abstract
Background: In recent years, several new technologies for small-animal imaging have been developed. In
particular, the use of ultrasound in animal imaging has focused on the investigation of accessible biological
structures such as the heart, of which it provides a morphological and functional assessment. The purpose of this
study was to investigate the role of micro-ultrasonography (μ-US) in a longitudinal study on BIO14.6
cardiomyopathic hamsters treated with gene therapy.
Methods: Thirty hamsters were divided into three groups (n = 10): Group I, untreated BIO 14.6 hamsters; Group II,
BIO 14.6 hamsters treated with gene therapy; Group III, untreated wild type (WT) hamsters. All hamsters underwent
serial μ-US sessions and were sacrificed at predetermined time points.
Results: μ-US revealed: in Group I, progressive dilation of the left ventricle with a change in heart morphology
from an elliptical to a more spherical shape, altered configuration of the mitral valve and subvalvular apparatus,
and severe reduction in ejection fraction; in Group II, mild decrease in contractile function and ejection fraction; in
Group III, normal cardiac chamber morphology and function. There was a negative correlation between the
percentage of fibrosis observed at histology and the ejection fraction obtained on μ-echocardiography (Spearman
r: -0.839; p < 0.001).
Conclusions: Although histological examination remains indispensable for a conclusive diagnosis, high-frequency
μ-echocardiography, thanks to the high spatial and contrast resolution, can be considered sufficient for monitoring
therapeutic efficacy and/or the progression of dilated cardiomyopathy, providing an alternative tool for repeatable
and noninvasive evaluation.
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Introduction
In recent years, several new technologies for small-ani-
mal imaging have been developed including micro-
radiography (μ-XR), micro-computed tomography (μ-
CT), micro-magnetic resonance imaging (μ-MRI),
micro-positron emission tomography (μ-PET) and
micro-ultrasonography (μ-US). These technologies have
allowed for a better evaluation of the efficacy of diag-
nostic and therapeutic protocols in the field of pre-
clinical research. In particular, the use of ultrasound in
animal imaging has focused on the investigation of
accessible biological structures such as the heart, of
which it provides a morphological and functional assess-
ment [1-3].
Muscular dystrophies constitute a heterogeneous
group of degenerative diseases characterized by a pro-
gressive wasting and weakening of skeletal muscle, of
varying severity and distribution [4]. The ethiopathogen-
esis of these disorders is ascribed to mutations in genes
coding for the proteins forming the dystrophin-asso-
ciated protein complex (DAPC) mutations, which cause
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any medium, provided the original work is properly cited.loss of integrity of the sarcolemma rendering the muscle
fibers more prone to injury [5].
The most frequent types of muscular dystrophy,
Duchenne and Becker, are characterized by an X-linked
pattern of inheritance, but less common forms also exist
having both dominant and recessive autosomal trans-
mission: limb-girdle muscular dystrophies (LGMD). The
most severe forms of LGMD (LGMD2D, LGMD2E,
LGMD2C and LGMD2F) are due to mutations of alpha-
sarcoglycan (SG), beta-SG, gamma-SG and delta-SG,
they typically arise in infancy and are often associated
with the development of dilated cardiomyopathy [6].
In order to facilitate the understanding of the etiologi-
cal and pathophysiological mechanisms underlying the
different forms of muscular dystrophy and to devise and
test new treatment protocols, several animal models
have been developed. The BIO 14.6 hamster faithfully
reproduces the LGMD2F phenotype seen in humans. In
this animal model, the absence of delta-SG from the
membrane of skeletal and cardiac muscle results in a
secondary deficiency of alpha-, beta-, and gamma-SG.
These hamsters exhibit a gradual loss of muscle strength
and the progressive development of dilated cardiomyo-
pathy, with a mean lifespan of 11 months, in contrast to
the 22 months of the wild type (WT) hamsters [7,8].
T h eu s e ,i ng e n et h e r a p y ,o fa d e n o - a s s o c i a t e dv i r u s e s
(AAV) - nonpathogenic, single-stranded DNA viruses of
the Parvovirus family - as vectors for cDNA containing
the WT delta-SG gene, has been shown to be effective
in producing a regression of the pathological phenotype
[9,10,6].
T h i ss t u d ya i m e dt od e f i n et h er o l eo fμ-US in the
longitudinal study of BIO 14.6 hamsters with dilated
cardiomyopathy treated with gene therapy.
Methods
All procedures performed on the animals received prior
approval from our institutional ethics committee. Thirty
male hamsters were used; they were maintained on
light/dark cycles of 12/12 h and had free access to food
and water.
The hamsters were divided into three groups of 10
animals each:
- Group I: untreated BIO 14.6 hamsters;
- Group II: BIO 14.6 hamsters which received an
intraperitoneal injection of AAV2/8-CMV-hSCGD
(Recombinant AAV vector containing human delta-sar-
coglycan cDNA, driven by the cytomegalovirus promo-
ter packaged into AAV2 serotype transcapsidated with
AAV8 serotype) after 2 weeks of age and an intrajugular
injection of AAV2/1(AAV2 serotype transcapsidated
with AAV1 serotype)-CMV-hSCGD after 5 months of
age. The AAV were transcapsidated to improve cellular
targeting. A different AAV serotype was used in the
second injection to prevent immune response against
the viral capsid.
- Group III: untreated WT hamsters;
All hamsters were examined with μ-echocardiography
and sacrificed with an intrapulmonary injection of 0.2
mg of Tanax at the time points and in the manner
shown in Additional file 1.
One- and two-dimensional echocardiography
Echocardiographic examinations were performed with a
VisualSonics Vevo 2100 unit, capable of recording over
750 frames per second and equipped with a high-fre-
quency (40 MHz) transducer.
During each μ-imaging session the hamsters received
inhalation anesthesia with isoflurane in oxygen (3-4%
for induction and 1.5% for maintenance). Heart rate and
body temperature were appropriately monitored and
remained constant also throughout the examination.
Eutermia was guaranteed by the use of a heating pad. In
order to prevent imaging artifacts each hamster was
immobilized and its chest hair was removed by applying
a calcium thioglycolate depilatory cream. The transducer
was fixed on a special arm. An appropriate amount of
heated sonographic gel (Aquasonic 100; Parker Labora-
tories, Inc, Fairfield, NJ) was applied to the shaved skin.
The echocardiographic study was performed in two-
dimensional (B-mode) and one-dimensional mode (M-
mode) in the following projections:
- Parasternal long axis
Once the hamster had been prepared for imaging on
the animal platform, the transducer was positioned
longitudinally to its body, along the right parasternal
line, with the index marker pointing to its head and
rotated about 35° counterclockwise.
The obtained B-mode image represents a section
across the long axis of the left ventricle, which allowed
visualization of the aortic root, outflow tract of the left
ventricle, delimited anteriorly by the interventricular
septum and posteriorly by the anterior flap of the mitral
valve (Figure 1a, b).
- Short parasternal axis
The B-mode parasternal short-axis view was obtained
from the long-axis view by rotating the transducer 90°
clockwise so that the scan plane was perpendicular to
the long-axis of the left ventricle. By moving the trans-
ducer downwards, cross-sectional views of the left ven-
tricle were obtained at various levels (mitral, papillary
muscles, cardiac apex) along its long axis, which enabled
an accurate assessment of cardiac morphometry and
global and segmental contractility. On the basis of the
B-mode cross-sectional images at the level of the papil-
lary muscles, the following left ventricle measurements
were acquired in M-mode: interventricular septum end-
diastolic (IVSdt) and end-systolic thickness (IVSst); left
Belfiore et al. Cardiovascular Ultrasound 2011, 9:39
http://www.cardiovascularultrasound.com/content/9/1/39
Page 2 of 6ventricular diameter in end-diastole (LVIDd) and end-
systole (LVISs); left ventricular posterior wall thickness
in diastole and systole (LVPWs, d); left ventricular mass
(LVmass); left ventricular volume (LVvol s, d) (Figure
2a, b).
- Apical
The bi-dimensional apical view was obtained from the
short-axis view, by tilting downwards as far as possible
the extremity of the animal platform where the ham-
ster’s head was placed and angling the base of the trans-
ducer towards the operator. This provided a four-
chamber view of the heart. By rotating the transducer
clockwise a two-chamber apical view was obtained
which is highly important in the study of cardiac con-
tractility (Figure 3a, b).
Left ventricular systolic function was evaluated by cal-
culating the ejection fraction (%EF); this was derived
from the left ventricular end-diastolic and end-systolic
volumes which were automatically generated by the
echocardiographic system software on the basis of the
short-axis M-mode measurements - in turn based on
the bi-dimensional images - according to the following
formula: (LVEDv -LVESv)/LVEDv × 100. Cardiac mass
was calculated with the following formula: 0.8 (1.04
([LVEDd + PWDt + IVSDt]3- [LVEDd]3)) + 0.6.
Histological examination
After sacrifice of the hamsters at the time points, the
cardiac muscle was completely removed and 7-10-
micron-thick cryosections were obtained.
The sections were stained with haematoxylin-eosin to
quantify the extent of necrotic areas; others were stu-
died after staining with Masson’s trichrome stain to
assess for the presence of fibrotic areas.
Statistical analysis
The data are reported as mean ± standard deviation.
The correlation between percentage of fibrosis at his-
tology and ejection fraction at echocardiography was
analyzed with the Spearman rank test. Values of p <
0.05 were considered statistically significant.
Results
Echocardiography
The results of the echocardiographic study are summar-
ized in Additional file 2.
Figure 1 (a, b) B-mode image of the left ventricle in long-axis view during systole (a) and diastole (b). The red arrow shows the
interventricular septum, the yellow arrow indicates the aorta and the blue arrow the papillary muscle.
Figure 2 (a, b) B-mode image of the left ventricle. Short-axis view during systole (a) and diastole (b). The red arrow shows the papillary
muscle, the yellow arrow indicates the thickness of the left ventricle anterior wall. This is the best window for evaluating contractility.
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cardiographic study of the hamsters of Group I
(untreated BIO 14.6) revealed: dilation of the left ventri-
cle with a change in heart morphology from the physio-
logical elliptical shape to a more spherical shape, altered
spatial configuration of the mitral valve and subvalvular
apparatus, widening of the left atrium and right atrium
and ventricle with severe reduction in ejection fraction
at 8 months (Figure 4a, b, c).
In the hamsters of Group II (treated BIO 14.6), echo-
cardiography showed a mild decrease in contractile
function and ejection fraction, in presence of a left ven-
tricular wall thickness at the lower limits of normal and
mild dilation of the cardiac chambers.
In the hamsters of Group III (untreated WT), echo-
cardiography revealed normal morphology and function
of the cardiac chambers.
There was a statistically significant negative correla-
tion between the percentage of fibrosis found at histol-
ogy and the ejection fraction (Spearman r: - 0.8389; p <
0.001) (see Additional file 3).
Histological examination
Histological examination performed on the hamsters of
Group I revealed degeneration of the myocytes, necrosis
and marked fibrosis (see Additional file 4). The hamsters
of Group II showed complete absence of areas of necro-
sis and/or fibrosis, a situation that did not differ signifi-
cantly from that of the hamsters of Group III (Figure
5a, b, c).
Discussion
Noninvasive small-animal imaging has taken on an
increasing role in preclinical research as to become an
independent sector. Today, the availability of advanced
imaging techniques constitutes a key factor in the suc-
cess and timeliness of research thanks to the possibility
of conducting longitudinal studies on the same animal
[1]. Among these techniques, μ-echocardiography is an
inexpensive, repeatable, fast and noninvasive modality
a n da ss u c hi ti sp a r t i c u l a r l ys u i t e dt ot h i st y p eo f
experimental projects.
Noninvasive imaging helps to render animal experi-
ments more ethically acceptable as it is compliant with
the principles of the 3Rs (Replacement, Reduction,
Refinement) formulated in 1959, which consider the
possibility of replacing [Replacement], where possible,
the use and/or sacrifice of the animal with other equally
effective methods, reducing [Reduction] the number of
experiments, and refining [Refinement] techniques to
Figure 3 (a, b) Apical two-chamber view showing right ventricle (red arrow) and left ventricle (blue arrow) during systole (a) and
diastole (b). The ejection fraction and shortening fraction were calculated with this view.
Figure 4 (a, b, c) Image (a) of group I (untreated) BIO 14.6 hamsters shows reduced myocardial contractility and progression to
dilated cardiomyopathy. The blue arrow indicates thinning of the left ventricle wall. Image (b) of treated BIO 14.6 hamsters reveals slightly
reduced myocardial contractility, and preservation of the myocardial wall. Image (c) of wild type hamsters shows preservation of the myocardial
wall and no disease state.
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study aimed to demonstrate that μ-echocardiography is
a powerful tool in support of the 3R policy. Although
the modality is well known as a non-invasive, reproduci-
ble and inexpensive diagnostic modality, only recently
have been developed systems, which allow for a more
detailed study of cardiac function in small animals.
Thanks to high resolution images (40 MHz) acquisition,
with a potential for recording more than 750 frames per
second, these systems provide an analysis similar to that
obtained in humans and therefore a more objective
result of echocardiographic imaging [13,14]. This latter
aspect is crucial in order to reduce the number of sacri-
fices during the experiment, allowing several assess-
ments during follow-up. This should not be regarded as
a marginal issue particularly if we consider that, like
humans, animals show individual variability in the
course of the disease, and further assessment can
improve our understanding of the evolution of the
disease.
Echocardiography is widely used for the morphological
and functional evaluation of the heart [15] as it permits
an accurate analysis of cardiac anatomy and haemody-
namics facilitating the understanding of the pathophy-
siological mechanisms underlying the disease being
studied. This technique has been able to monitor the
effects of gene therapy on the cardiac function of BIO
14.6 hamsters with dilated cardiomyopathy.
Only few ultrasound systems to date have been able to
provide high-quality echocardiographic studies on ham-
sters, because of inadequate image resolution and an
inability to process quantitative data. In the present
study, despite the high hamsters heart rate, the μ-echo-
cardiographic examination allowed to obtain a precise
estimation of heart function parameters thanks to high-
frequency transducers (40 MHz).
Indeed, μ-echocardiography is ideal for phenotyping
and estimating left ventricular function; as a fast and
noninvasive method, it can also be used in animals in
suboptimal physical condition.
The lack of the gene coding for delta-SG in these ani-
mals entails a loss of sarcolemmal integrity with necrosis
of the cardiomyocytes; this promotes the development
of an inflammatory response with fibrotic degeneration.
By limiting myocardial elasticity, fibrotic replacement
reduces contractile function with progressive stretching
and thinning of the fibrotic regions, leading to progres-
sive dilation.
The increase in ventricular volume worsens the systo-
lic dysfunction associated with mitral valve insufficiency,
leading to low-output heart failure.
Serial echocardiography successfully documented this
evolution in the untreated BIO 14.6 hamsters, but not
in the treated hamsters. Gene therapy was in fact able
to almost completely preserve cardiac function in the
dystrophic hamsters, which showed similar morphology,
echocardiographic parameters and survival to the wild
type hamsters.
In order to confirm the role of this method in moni-
toring the evolution of cardiomyopathy, samples of myo-
cardial tissue were studied by histological examination.
The estimation of injury obtained at microscopic analy-
sis correlated with that of the μ-echocardiographic
study.
Our experience showed that μ-US imaging applied to
the study of cardiomyopathy in BIO 14.6 hamsters,
thanks to the high spatial and contrast resolution, pro-
vides an estimation of morphological changes which
well correlate with the histological findings, and may
help to reduce the animals sacrifice.
Even though histology remains indispensable for a
definite diagnosis, echocardiography can be used to
monitor the efficacy of treatment and/or the progres-
sion of dilated cardiomyopathy and constitutes an
alternative tool for a repeatable and noninvasive
assessment.
Figure 5 (a, b, c) Delivery of the delta-sarcoglycan gene through AAV diminishes the percentage of fibrotic areas in hearts.
Haematoxylin-eosin staining on frozen sections: untreated (a), treated (b) and wild type (c). The red arrow indicates the fibrotic areas (a), which
are absent from the treated and wild type groups. All frozen sections were analyzed at 7 months of age. Original magnification 20×.
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ging, the use of contrast media and higher-frequency
transducers will help to refine the characterization of
sonographic patterns of disease also reducing both the
time and cost of longitudinal studies.
Additional material
Additional file 1: Timing and modality of examination of the
hamsters. “Arrow” indicates the timing of gene therapy administration;
“heart” represents the time points at which the μ-US examination was
performed in each animal; “block” corresponds to the sacrifice of animals
to proceed with the histological examination. For each time point, two
animals were sacrificed in each group. Point: natural death (Group I:
10,65 ± 0,29 months; Group II: 21,30 ± 0,54 months; Group III 21,85 ±
0,26) the data are reported as mean ± standard deviation.
Additional file 2: Results of the echocardiographic measurements.
IVSs, d - interventricular septum thickness during diastole and systole;
LVIDs, d - left ventricular internal diameter during diastole and systole;
LVPWs, d - left ventricular posterior wall thickness during diastole and
systole; EF% - ejection fraction percentage; LV mass - left ventricular
mass; LVvols, d - left ventricular volume during systole and diastole).
Additional file 3: Correlation between percentage of fibrosis and
ejection fraction. The graph shows a significant negative correlation
between the percentage of fibrosis and the ejection fraction (Spearman
r:-0.8389; p < 0.001)
Additional file 4: Percentage of total fibrosis at histological
examination and ejection fraction at micro-echocardiography
evaluation.
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